Substance / Medication

Telotristat

Overview

Active Ingredient
telotristat
RxNorm CUI
1872382

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Hörsch Dieter, Anthony Lowell, Gross David J et al. · Neuroendocrinology · 2022
PMID: 33940581ObservationalFull text (PMC)
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust Kelly, Maschio Michael, Kohli Michele et al. · Pharmacoeconomics · 2020
PMID: 32157590Observational
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg Jonathan, Joish Vijay N, Giacalone Susan et al. · Oncologist · 2019
PMID: 31189618ObservationalFull text (PMC)
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
Anthony Lowell, Ervin Claire, Lapuerta Pablo et al. · Clin Ther · 2017
PMID: 29074312Observational
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.
Kasi Pashtoon Murtaza · Pancreas · 2018
PMID: 29232344Case Report
Telotristat ethyl affects tumour-fibroblast crosstalk in small intestinal neuroendocrine tumours.
Hodgetts Harry, Martins Maria Castanho, Chen Luohai et al. · J Neuroendocrinol · 2025
PMID: 40998421OtherFull text (PMC)
Use of perioperative telotristat in a patient with carcinoid heart disease.
Flynn Maria, Noss Christopher, Miller Robert et al. · Endocrinol Diabetes Metab Case Rep · 2024
PMID: 38377684OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telotristat (substance)
SNOMED CT
733734004
UMLS CUI
C3884837
RxNorm CUI
1872382

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.